Lilly experimental drug cuts weight by nearly 21% in late-stage type 2 diabetes trial
Eli Lilly said its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of body weight in a late-stage clinical trial, Reuters reported.
Sept 29 (Reuters) — Eli Lilly said on Tuesday its experimental drug helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar) ((Kamal.Choudhury@thomsonreuters.com;)